ProQR Announces Year End 2023 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
ProQR Therapeutics N.V. (PRQR) PT Raised to $2.50 at Chardan Capital Markets
March 14, 2024 5:02 AM EDTChardan Capital Markets analyst Keay Nakae raised the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $2.50 (from $2.00) while maintaining a Buy rating.
The analyst comments "We maintain our Buy rating, and increase our 12-month price target to $2.50. We believe that ProQR's Axiomer RNA... More
